Positive progression-free survival and overall survival data from Merck & Co. Inc.’s high profile KEYNOTE-024 trial testing Keytruda (pembrolizumab) in patients with previously untreated advanced non-small cell lung cancer (NSCLC) positions Keytruda to beat Bristol-Myers Squibb Co.’s Opdivo (nivolumab) to a first-line lung cancer indication.
The winner long-term in the high stakes market remains very much up in the air, however, as the details of the trial were not released. Bristol’s trial in a similar patient population, CheckMate 026, is still ongoing, with data anticipated in the third quarter, and there is still a big question about the optimal threshold for testing tumors for PD-L1 expression
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?